The market is driven by a rise in aesthetic procedures and better patient outcomes.
Although the pandemic had a major impact on Asia Pacific’s aesthetic injectables market in Q2, the market started to recover from Q3 as several clinics began resuming elective services, according to a report from GlobalData.
Driven by a growing number of aesthetic procedures, technological advancements, growing urban population, preference to non-surgical and minimally invasive procedures, and better patient outcomes, the market is projected to hit $3.8b in 2030.
Of these, hyaluronic acid fillers have become one of the most popular kinds of injectables due to their ease of use, low complication profile, and high patient satisfaction. These currently account for around 75% of the aesthetic injectables market.
Currently, China performs more number of aesthetic injectable procedures and dominates the market, followed by Japan and South Korea. Galderma SA and AbbVie Inc are the leading players in the region, accounting for more than 70% of the market share.
GlobalData’s medical devices analyst Pratibha Thammanabhatla said that as use of aesthetic injectables gain momentum and new products emerge, cosmetic physicians should develop expertise on the products available in the market, their limitations, and anatomic principles.
“This will result in improved outcomes while avoiding any serious complications, diversify the clinical applications and further drive the market,” Thammanabhatla said.
Do you know more about this story? Contact us anonymously through this link.